Literature DB >> 26851259

Increased susceptibility of Cftr-/- mice to LPS-induced lung remodeling.

Emanuela M Bruscia1, Ping-Xia Zhang2, Christina Barone1, Bob J Scholte3, Robert Homer4, Diane S Krause5, Marie E Egan6.   

Abstract

Cystic fibrosis (CF) is caused by homozygous mutations of the CF transmembrane conductance regulator (CFTR) Cl(-) channel, which result in chronic pulmonary infection and inflammation, the major cause of morbidity and mortality. Although these processes are clearly related to each other, each is likely to contribute to the pathology differently. Understanding the contribution of each of these processes to the overall pathology has been difficult, because they are usually so intimately connected. Various CF mouse models have demonstrated abnormal immune responses compared with wild-type (WT) littermates when challenged with live bacteria or bacterial products acutely. However, these studies have not investigated the consequences of persistent inflammation on lung tissue in CF mice, which may better model the lung pathology in patients. We characterized the lung pathology and immune response of Cftr(-/-) (CF) and Cftr(+/+) (WT) mice to chronic administration of Pseudomonas aeruginosa lipopolysaccharide (LPS). We show that, after long-term repeated LPS exposure, CF mice develop an abnormal and persistent immune response, which is associated with more robust structural changes in the lung than those observed in WT mice. Although CF mice and their WT littermates develop lung pathology after chronic exposure to LPS, the inflammation and damage resolve in WT mice. However, CF mice do not recover efficiently, and, as a consequence of their chronic inflammation, CF mice are more susceptible to morphological changes and lung remodeling. This study shows that chronic inflammation alone contributes significantly to aspects of CF lung pathology.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  IFN-γ-induced protein 10; cystic fibrosis; inflammation

Mesh:

Substances:

Year:  2016        PMID: 26851259      PMCID: PMC4836110          DOI: 10.1152/ajplung.00284.2015

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  36 in total

1.  Inflammatory mediators in CF patients.

Authors:  Jay B Hilliard; Michael W Konstan; Pamela B Davis
Journal:  Methods Mol Med       Date:  2002

2.  Functional IL-10 deficiency in the lung of cystic fibrosis (cftr(-/-)) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages.

Authors:  Jindrich Soltys; Tracey Bonfield; James Chmiel; Melvin Berger
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

3.  Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice.

Authors:  A M van Heeckeren; J Tscheikuna; R W Walenga; M W Konstan; P B Davis; B Erokwu; M A Haxhiu; T W Ferkol
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

4.  Genetic requirements for bone marrow transplantation for stem-cell-defective W/Wv mice.

Authors:  S J Sharkis; R Cahill; A Ahmed; W W Jedrzejczak; K W Sell
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

Review 5.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

6.  An animal model for cystic fibrosis made by gene targeting.

Authors:  J N Snouwaert; K K Brigman; A M Latour; N N Malouf; R C Boucher; O Smithies; B H Koller
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

7.  Activation of the STAT pathway in acute lung injury.

Authors:  Mariano Severgnini; Satoe Takahashi; Liliana M Rozo; Robert J Homer; Charles Kuhn; Jhung W Jhung; George Perides; Michael Steer; Paul M Hassoun; Barry L Fanburg; Brent H Cochran; Amy R Simon
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-01-16       Impact factor: 5.464

8.  Subchronic endotoxin inhalation causes persistent airway disease.

Authors:  D M Brass; J D Savov; S H Gavett; N Haykal-Coates; D A Schwartz
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-06-06       Impact factor: 5.464

9.  Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model.

Authors:  Peter R Durie; Geraldine Kent; M James Phillips; Cameron A Ackerley
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

Review 10.  State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?

Authors:  James F Chmiel; Pamela B Davis
Journal:  Respir Res       Date:  2003-08-27
View more
  14 in total

1.  Fibrocyte accumulation in the lungs of cystic fibrosis patients.

Authors:  Rajesh K Kasam; Prathibha R Gajjala; Anil G Jegga; Jennifer A Courtney; Scott H Randell; Elizabeth L Kramer; John P Clancy; Satish K Madala
Journal:  J Cyst Fibros       Date:  2020-06-25       Impact factor: 5.482

Review 2.  Ion channels of the lung and their role in disease pathogenesis.

Authors:  Rafal Bartoszewski; Sadis Matalon; James F Collawn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-10-12       Impact factor: 5.464

Review 3.  Animal models of cystic fibrosis in the era of highly effective modulator therapies.

Authors:  Barbara R Grubb; Alessandra Livraghi-Butrico
Journal:  Curr Opin Pharmacol       Date:  2022-05-13       Impact factor: 4.768

4.  AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations.

Authors:  Rebecca J Darrah; Frank J Jacono; Neha Joshi; Anna L Mitchell; Abdus Sattar; Cara K Campanaro; Paul Litman; Jennifer Frey; David E Nethery; Eric S Barbato; Craig A Hodges; Harriet Corvol; Garry R Cutting; Michael R Knowles; Lisa J Strug; Mitchell L Drumm
Journal:  J Cyst Fibros       Date:  2018-06-22       Impact factor: 5.482

5.  Donor-defined mesenchymal stem cell antimicrobial potency against nontuberculous mycobacterium.

Authors:  Tracey L Bonfield; Morgan T Sutton; David R Fletcher; Michael A Folz; Vaishnavi Ragavapuram; Rodrigo A Somoza; Arnold I Caplan
Journal:  Stem Cells Transl Med       Date:  2021-05-04       Impact factor: 6.940

Review 6.  Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.

Authors:  Anjali Y Bhagirath; Yanqi Li; Deepti Somayajula; Maryam Dadashi; Sara Badr; Kangmin Duan
Journal:  BMC Pulm Med       Date:  2016-12-05       Impact factor: 3.317

Review 7.  Strategies for the etiological therapy of cystic fibrosis.

Authors:  Luigi Maiuri; Valeria Raia; Guido Kroemer
Journal:  Cell Death Differ       Date:  2017-09-22       Impact factor: 15.828

8.  Ezrin links CFTR to TLR4 signaling to orchestrate anti-bacterial immune response in macrophages.

Authors:  Caterina Di Pietro; Ping-Xia Zhang; Timothy K O'Rourke; Thomas S Murray; Lin Wang; Clemente J Britto; Jonathan L Koff; Diane S Krause; Marie E Egan; Emanuela M Bruscia
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

Review 9.  Cytokine-Regulation of Na+-K+-Cl- Cotransporter 1 and Cystic Fibrosis Transmembrane Conductance Regulator-Potential Role in Pulmonary Inflammation and Edema Formation.

Authors:  Sarah Weidenfeld; Wolfgang M Kuebler
Journal:  Front Immunol       Date:  2017-04-07       Impact factor: 7.561

Review 10.  Airway disease phenotypes in animal models of cystic fibrosis.

Authors:  Alexandra McCarron; Martin Donnelley; David Parsons
Journal:  Respir Res       Date:  2018-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.